Key Points
-
Myelodysplastic syndrome (MDS) is one of the most common haematological malignancies and is associated with increased age and exposure to previous chemotherapy and radiation. It is characterized by cytopenias, morphological dysplasia and a propensity to transform to acute myeloid leukaemia (AML).
-
Clonal haematopoiesis of indeterminate potential (CHIP) is a condition in which a substantial percentage of haematopoietic cells bear a somatic mutation in a gene that is recurrently mutated in haematological malignancies, including MDS. CHIP is strongly associated with age and an increased risk of haematological malignancy.
-
More than 50 recurrently mutated genes have been identified in MDS, many of which occur in genes encoding RNA splicing factors, epigenetic regulators, haematopoietic transcription factors and kinase signalling pathways.
-
Individual mutations in MDS are associated with specific morphological findings, have independent prognostic significance and can predict response to therapy in some cases.
-
AML that arises out of a pre-existing MDS can be distinguished from de novo AML by the presence of specific mutations, such as those in splicing factors and certain epigenetic regulators.
-
Some mutations are associated with increased sensitivity or resistance to standard therapeutic interventions, providing new targets for the development of novel therapeutic agents.
-
Currently, allogeneic haematopoietic stem cell transplantation is the only known curative treatment for MDS.
Abstract
Myelodysplastic syndrome (MDS) is a clonal disease that arises from the expansion of mutated haematopoietic stem cells. In a spectrum of myeloid disorders ranging from clonal haematopoiesis of indeterminate potential (CHIP) to secondary acute myeloid leukaemia (sAML), MDS is distinguished by the presence of peripheral blood cytopenias, dysplastic haematopoietic differentiation and the absence of features that define acute leukaemia. More than 50 recurrently mutated genes are involved in the pathogenesis of MDS, including genes that encode proteins involved in pre-mRNA splicing, epigenetic regulation and transcription. In this Review we discuss the molecular processes that lead to CHIP and further clonal evolution to MDS and sAML. We also highlight the ways in which these insights are shaping the clinical management of MDS, including classification schemata, prognostic scoring systems and therapeutic approaches.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arber, D. A. et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 127, 2391–2405 (2016).
Liew, E. & Owen, C. Familial myelodysplastic syndromes: a review of the literature. Haematologica 96, 1536–1542 (2011).
Cogle, C. R. Incidence and burden of the myelodysplastic syndromes. Curr. Hematol. Malignancy Rep. 10, 272–281 (2015).
Ma, X., Does, M., Raza, A. & Mayne, S. T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109, 1536–1542 (2007).
Sekeres, M. A. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J. Natl Compr. Canc. Netw. 9, 57–63 (2011).
Greenberg, P. L. et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120, 2454–2465 (2012).
Kantarjian, H. et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113, 1351–1361 (2008).
Malcovati, L. et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 96, 1433–1440 (2011).
Bejar, R. et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364, 2496–2506 (2011). The first paper showing that individual MDS-associated mutations are associated with patient outcomes.
Bejar, R. et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J. Clin. Oncol. 30, 3376–3382 (2012).
Woll, P. S. et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 25, 794–808 (2014). This paper describes the most detailed characterization of MDS stem cells.
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014). Description of CHIP and its association with overall and cardiovascular mortality.
Miyamoto, T., Weissman, I. L. & Akashi, K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc. Natl Acad. Sci. USA 97, 7521–7526 (2000).
Nilsson, L. et al. Involvement and functional impairment of the CD34+CD38−Thy-1+ hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 100, 259–267 (2002).
Nilsson, L. et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 96, 2012–2021 (2000).
Odejide, O. et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 123, 1293–1296 (2014).
Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25–38 (2011).
Steensma, D. P. Myelodysplastic syndromes: diagnosis and treatment. Mayo Clin. Proc. 90, 969–983 (2015).
Busque, L. et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 44, 1179–1181 (2012).
Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 1472–1478 (2014).
Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014).
Steensma, D. P. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9–16 (2015).
Cargo, C. A. et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood 126, 2362–2365 (2015).
Kwok, B. et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood 126, 2355–2361 (2015).
Haferlach, T. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241–247 (2014). The largest panel of MDS patients sequenced to date.
Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616–3627 (2013). Identification of early and late mutations in MDS using variant allele fractions.
Hughes, A. E. et al. Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet. 10, e1004462 (2014).
Lindsley, R. C. et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125, 1367–1376 (2015). Characterization of different mutational spectra found in de novo AML and sAML.
Corces-Zimmerman, M. R., Hong, W. J., Weissman, I. L., Medeiros, B. C. & Majeti, R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl Acad. Sci. USA 111, 2548–2553 (2014).
Murphy, D. M. et al. NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. Leukemia 27, 2077–2081 (2013).
Takahashi, K. et al. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia 27, 2081–2083 (2013).
Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264–278 (2012).
Gerstung, M. et al. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat. Commun. 6, 5901 (2015).
Kon, A. et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat. Genet. 45, 1232–1237 (2013).
Bejar, R. et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J. Clin. Oncol. 32, 2691–2698 (2014).
Ortmann, C. A. et al. Effect of mutation order on myeloproliferative neoplasms. N. Engl. J. Med. 372, 601–612 (2015). The first demonstration that mutational order alters clinical phenotype and outcomes in MPN.
Jeromin, S. et al. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations. Haematologica 100, e125–e127 (2015).
Malcovati, L. et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood 126, 233–241 (2015).
Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506–510 (2012).
Garg, M. et al. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood 126, 2491–2501 (2015).
Jan, M. et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl Med. 4, 149ra118 (2012).
Shlush, L. I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328–333 (2014).
Klco, J. M. et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA 314, 811–822 (2015).
Walter, M. J. et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 27, 1275–1282 (2013).
Yoshizato, T. et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N. Engl. J. Med. 373, 35–47 (2015). The largest sequenced cohort of aplastic anaemia patients.
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153–158 (2007).
Colla, S. et al. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell 27, 644–657 (2015).
Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014).
Inoue, D., Bradley, R. K. & Abdel-Wahab, O. Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. Genes Dev. 30, 989–1001 (2016).
Graubert, T. A. et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat. Genet. 44, 53–57 (2012).
Papaemmanuil, E. et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365, 1384–1395 (2011).
Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64–69 (2011). Initial description of the finding of common splicing mutations in MDS.
Conte, S. et al. Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts. Br. J. Haematol. 171, 478–490 (2015).
Darman, R. B. et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 3' splice site selection through use of a different branch point. Cell Rep. 13, 1033–1045 (2015).
Kim, E. et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27, 617–630 (2015).
Ilagan, J. O. et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 25, 14–26 (2015).
Przychodzen, B. et al. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood 122, 999–1006 (2013).
Yang, L., Rau, R. & Goodell, M. A. DNMT3A in haematological malignancies. Nat. Rev. Cancer 15, 152–165 (2015).
Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424–2433 (2010).
Walter, M. J. et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25, 1153–1158 (2011).
Ko, M. et al. TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol. Rev. 263, 6–21 (2015).
Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930–935 (2009).
Lorsbach, R. B. et al. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 17, 637–641 (2003).
Ono, R. et al. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res. 62, 4075–4080 (2002).
Okano, M., Xie, S. & Li, E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat. Genet. 19, 219–220 (1998).
Kallin, E. M. et al. Tet2 facilitates the derepression of myeloid target genes during CEBPα-induced transdifferentiation of pre-B cells. Mol. Cell 48, 266–276 (2012).
Rasmussen, K. D. et al. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev. 29, 910–922 (2015).
Yamazaki, J. et al. TET2 mutations affect non-CpG island DNA methylation at enhancers and transcription factor-binding sites in chronic myelomonocytic leukemia. Cancer Res. 75, 2833–2843 CAN-14-0739 (2015).
Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 465, 966 (2010).
Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234 (2010).
Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17–30 (2011).
Losman, J. A. et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621–1625 (2013).
Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474–478 (2012). References 70–74 demonstrate that IDH mutations cause disease through the generation of a novel oncometabolite.
Challen, G. A. et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet. 44, 23–31 (2012).
Zhang, X. et al. DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat. Genet. 48, 1014–1023 (2016).
Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11–24 (2011).
Jeong, M. et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat. Genet. 46, 17–23 (2014).
Cao, R. et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039–1043 (2002).
Francis, N. J., Kingston, R. E. & Woodcock, C. L. Chromatin compaction by a polycomb group protein complex. Science 306, 1574–1577 (2004).
Wang, H. et al. Role of histone H2A ubiquitination in Polycomb silencing. Nature 431, 873–878 (2004).
Sashida, G. et al. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation. Nat. Commun. 5, 4177 (2014).
Gao, Z. et al. PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol. Cell 45, 344–356 (2012).
Gearhart, M. D., Corcoran, C. M., Wamstad, J. A. & Bardwell, V. J. Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets. Mol. Cell. Biol. 26, 6880–6889 (2006).
Huynh, K. D., Fischle, W., Verdin, E. & Bardwell, V. J. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev. 14, 1810–1823 (2000).
Damm, F. et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood 122, 3169–3177 (2013).
Scheuermann, J. C. et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 465, 243–247 (2010).
Abdel-Wahab, O. et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22, 180–193 (2012).
Balasubramani, A. et al. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1−BAP1 complex. Nat. Commun. 6, 7307 (2015).
Cao, Q. et al. BCOR regulates myeloid cell proliferation and differentiation. Leukemia 30, 1155–1165 (2016).
Thota, S. et al. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood 124, 1790–1798 (2014).
Losada, A. Cohesin in cancer: chromosome segregation and beyond. Nat. Rev. Cancer 14, 389–393 (2014).
Horsfield, J. A. et al. Cohesin-dependent regulation of Runx genes. Development 134, 2639–2649 (2007).
Leeke, B., Marsman, J., O'Sullivan, J. M. & Horsfield, J. A. Cohesin mutations in myeloid malignancies: underlying mechanisms. Exp. Hematol. Oncol. 3, 13 (2014).
Marsman, J. et al. Cohesin and CTCF differentially regulate spatiotemporal runx1 expression during zebrafish development. Biochim. Biophys. Acta 1839, 50–61 (2014).
Mazumdar, C. et al. Leukemia-associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation. Cell Stem Cell 17, 675–688 (2015).
Hahn, C. N. et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat. Genet. 43, 1012–1017 (2011).
Ito, Y., Bae, S. C. & Chuang, L. S. The RUNX family: developmental regulators in cancer. Nat. Rev. Cancer 15, 81–95 (2015).
Zhang, M. Y. et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat. Genet. 47, 180–185 (2015).
Growney, J. D. et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 106, 494–504 (2005).
Owen, C. J. et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 112, 4639–4645 (2008).
Tsai, F. Y. et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 371, 221–226 (1994).
Bejar, R. et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 124, 2705–2712 (2014).
Rampal, R. et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 9, 1841–1855 (2014).
Wang, Y. et al. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol. Cell 57, 662–673 (2015).
Soenen, V. et al. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood 91, 1008–1015 (1998).
Rucker, F. G. et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 119, 2114–2121 (2012).
Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 307–315 (2004).
Kaneko, H., Misawa, S., Horiike, S., Nakai, H. & Kashima, K. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 85, 2189–2193 (1995).
Swisher, E. M. et al. Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma. JAMA Oncol. 2, 370–372 (2016).
Wong, T. N. et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518, 552–555 (2015). TP53 mutant HSCs expand preferentially during treatment with chemotherapy, explaining their increased frequency in therapy-related disease.
Zhao, Z. et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 24, 1389–1402 (2010).
Marusyk, A., Porter, C. C., Zaberezhnyy, V. & DeGregori, J. Irradiation selects for p53-deficient hematopoietic progenitors. PLoS Biol. 8, e1000324 (2010).
Walter, M. J. et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366, 1090–1098 (2012).
Furitsu, T. et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92, 1736–1744 (1993).
Kottaridis, P. D. et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98, 1752–1759 (2001).
Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779–1790 (2005).
Makishima, H. et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J. Clin. Oncol. 27, 6109–6116 (2009).
Pardanani, A. D. et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108, 3472–3476 (2006).
Sanada, M. et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 460, 904–908 (2009).
Sargin, B. et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 110, 1004–1012 (2007).
Saur, S. J., Sangkhae, V., Geddis, A. E., Kaushansky, K. & Hitchcock, I. S. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood 115, 1254–1263 (2010).
Javadi, M., Richmond, T. D., Huang, K. & Barber, D. L. CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN. J. Biol. Chem. 288, 19459–19470 (2013).
Haase, D. et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110, 4385–4395 (2007).
Bochtler, T., Frohling, S. & Kramer, A. Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia. Leukemia 29, 1243–1252 (2015).
Bernasconi, P. et al. Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution. Ann. Hematol. 89, 545–551 (2010).
Wang, H., Wang, X. Q., Xu, X. P. & Lin, G. W. Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome. Cancer Genet. Cytogenet. 196, 159–166 (2010).
Komrokji, R. S., Padron, E., Ebert, B. L. & List, A. F. Deletion 5q MDS: molecular and therapeutic implications. Best practice and research. Clin. Haematol. 26, 365–375 (2013).
Van den Berghe, H. et al. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 251, 437–438 (1974).
Chen, T. H. et al. Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice. Blood 117, 1530–1539 (2011).
Kumar, M. S. et al. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood 118, 4666–4673 (2011).
Starczynowski, D. T. et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat. Med. 16, 49–58 (2010).
Stoddart, A. et al. Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. Blood 123, 1069–1078 (2014).
Grisendi, S. et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437, 147–153 (2005).
Varney, M. E. et al. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling. J. Exp. Med. 212, 1967–1985 (2015).
DeWard, A. D., Leali, K., West, R. A., Prendergast, G. C. & Alberts, A. S. Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice. PLoS ONE 4, e7102 (2009).
Graubert, T. A. et al. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PloS ONE 4, e4583 (2009).
Polprasert, C. et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell 27, 658–670 (2015).
Schneider, R. K. et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 26, 509–520 (2014).
Ebert, B. L. et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451, 335–339 (2008).
Barlow, J. L. et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q− syndrome. Nat. Med. 16, 59–66 (2010).
Schneider, R. K. et al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat. Med. 22, 288–297 (2016).
Ludwig, L. S. et al. Altered translation of GATA1 in Diamond-Blackfan anemia. Nat. Med. 20, 748–753 (2014).
Vlachos, A. et al. Diminutive somatic deletions in the 5q region lead to a phenotype atypical of classical 5q− syndrome. Blood 122, 2487–2490 (2013).
Kronke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature 523, 183–188 (2015). This study describes the mechanism of action of lenalidomide in MDS.
List, A. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355, 1456–1465 (2006). The first clinical trial demonstrating that lenalidomide improves outcomes in the 5q− syndrome.
Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345–1350 (2010).
Chen, C. et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 25, 652–665 (2014).
McNerney, M. E. et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood 121, 975–983 (2013).
Nikoloski, G. et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42, 665–667 (2010).
Fenaux, P. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet. Oncol. 10, 223–232 (2009). This clinical trial showed that 5-azacitidine improves survival in higher risk patients with MDS and led to its clinical approval.
Kantarjian, H. et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106, 1794–1803 (2006).
Traina, F. et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 28, 78–87 (2014).
Jadersten, M. et al. Clonal heterogeneity in the 5q− syndrome: 53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 94, 1762–1766 (2009).
Raza, A. et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111, 86–93 (2008).
Koreth, J. et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J. Clin. Oncol. 31, 2662–2670 (2013).
Della Porta, M. G. et al. Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J. Clin. Oncol. 30, 3627–3637 (2016).
Chaturvedi, A. et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 122, 2877–2887 (2013).
Wang, F. et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340, 622–626 (2013).
Chan, S. M. et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat. Med. 21, 178–184 (2015).
Fandy, T. E. et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114, 2764–2773 (2009).
Lee, S. C. et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat. Med. 22, 672–678 (2016).
Maxson, J. E. et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N. Engl. J. Med. 368, 1781–1790 (2013).
Meggendorfer, M. et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia 27, 1852–1860 (2013).
Mason, C. C. et al. Age-related mutations and chronic myelomonocytic leukemia. Leukemia 30, 906–913 (2016).
Lane, A. A. et al. Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia 27, 968–971 (2013).
Shen, W. et al. Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. J. Clin. Invest. 124, 4529–4538 (2014).
Wilson, D. B., Link, D. C., Mason, P. J. & Bessler, M. Inherited bone marrow failure syndromes in adolescents and young adults. Ann. Med. 46, 353–363 (2014).
Yamaguchi, H. et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 102, 916–918 (2003).
Yamaguchi, H. et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N. Engl. J. Med. 352, 1413–1424 (2005).
Mitchell, J. R., Wood, E. & Collins, K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402, 551–555 (1999).
Vulliamy, T. et al. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat. Genet. 36, 447–449 (2004).
Noetzli, L. et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat. Genet. 47, 535–538 (2015).
McBride, K. A. et al. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat. Rev. Clin. Oncol. 11, 260–271 (2014).
Hsu, A. P. et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 118, 2653–2655 (2011).
Ostergaard, P. et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat. Genet. 43, 929–931 (2011).
Lewinsohn, M. et al. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood 127, 1017–1023 (2016).
Boocock, G. R. et al. Mutations in SBDS are associated with Shwachman–Diamond syndrome. Nat. Genet. 33, 97–101 (2003).
Zhou, T., Kinney, M. C., Scott, L. M., Zinkel, S. S. & Rebel, V. I. Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research. Blood 126, 1057–1068 (2015).
Li, Q. et al. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Nature 504, 143–147 (2013).
Dolatshad, H. et al. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia 29, 1798 (2015).
Chan, C. K. et al. Endochondral ossification is required for haematopoietic stem-cell niche formation. Nature 457, 490–494 (2009).
Ding, L., Saunders, T. L., Enikolopov, G. & Morrison, S. J. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 481, 457–462 (2012).
Zhou, B. O., Yue, R., Murphy, M. M., Peyer, J. G. & Morrison, S. J. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 15, 154–168 (2014).
Raaijmakers, M. H. et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852–857 (2010).
Kode, A. et al. Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts. Nature 506, 240–244 (2014).
Schepers, K. et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 13, 285–299 (2013).
Epperson, D. E., Nakamura, R., Saunthararajah, Y., Melenhorst, J. & Barrett, A. J. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leukemia Res. 25, 1075–1083 (2001).
Molldrem, J. J. et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann. Intern. Med. 137, 156–163 (2002).
Saunthararajah, Y., Nakamura, R., Wesley, R., Wang, Q. J. & Barrett, A. J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 102, 3025–3027 (2003).
Sloand, E. M., Wu, C. O., Greenberg, P., Young, N. & Barrett, J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J. Clin. Oncol. 26, 2505–2511 (2008).
Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013).
Patel, J. P. et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079–1089 (2012).
Papaemmanuil, E. et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N. Engl. J. Med. 374, 2209–2221 (2016).
Boultwood, J., Dolatshad, H., Varanasi, S. S., Yip, B. H. & Pellagatti, A. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes. Adv. Biol. Regul. 54, 153–161 (2014).
Fenaux, P. et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118, 3765–3776 (2011).
Cordoba, I. et al. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer 118, 127–133 (2012).
Bacher, U. et al. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact. Br. J. Haematol. 164, 822–833 (2014).
Wang, S. A. et al. Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features. Leuk. Res. 35, 351–357 (2011).
Wong, A. K. et al. Loss of the Y chromosome: an age-related or clonal phenomenon in acute myelogenous leukemia/myelodysplastic syndrome? Arch. Pathol. Lab. Med. 132, 1329–1332 (2008).
Acknowledgements
This work was supported by grants from the US National Institutes of Health (NIH) (R01 HL082945 and R24 DK099808), the Department of Defense, the Edward P. Evans Foundation, the Leukemia and Lymphoma Society and the STARR Cancer Consortium to B.L.E.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.L.E. receives research funding from Celgene, consulting fees from H3 Biomedicine, and consulting fees and patent royalties from Genoptix. The other authors declare no competing interests.
Glossary
- Cytopenias
-
Decreased blood counts of any kind (white cells, red cells or platelets).
- Blasts
-
Immature, hypofunctional leukaemic cells found in the peripheral blood or bone marrow.
- Secondary AML
-
(sAML). Acute myeloid leukaemia (AML) that arises out of a pre-existing myeloid neoplasm such as myelodysplastic syndrome (MDS) or myeloproliferative neoplasms. Distinguished from MDS by the presence of 20% or more blasts in the bone marrow or peripheral blood.
- Lineage
-
A collection of cell surface markers that defines mature blood cells, including B cells, T cells, monocytes, granulocytes and red blood cells.
- 5q− syndrome
-
Myelodysplastic syndrome associated with isolated deletion of chromosome 5q and characterized by a macrocytic anaemia, normal or elevated platelet count, a low marrow blast count and a relatively indolent course.
- Paroxysmal nocturnal haemoglobinuria
-
(PNH). Caused by mutations in the phosphatidylinositol glycan anchor biosynthesis class A (PIGA) gene leading to the loss of glycosylphosphatidylinositol (GPI), a chemical linker that functions to anchor several proteins to blood cell membranes including those that block complement-mediated haemolysis.
- Aplastic anaemia
-
(AA). Pancytopenia in the setting of aplastic bone marrow caused by immune-mediated destruction of haematopoietic progenitors. It is often difficult to distinguish morphologically from hypoplastic myelodysplastic syndrome.
- Hypoplastic MDS
-
Myelodysplastic syndrome (MDS) with low bone marrow cellularity. Hypoplastic MDS can be difficult to distinguish from aplastic anaemia owing to the small number of cells available to evaluate for morphological dysplasia.
- Mean corpuscular volume
-
(MCV). A measure of the average volume of red blood cells. Increased size is associated with abnormal or delayed red blood cell differentiation.
- Clonal haematopoiesis of indeterminate potential
-
(CHIP). The presence of a somatic mutation associated with haematological malignancy at a variant allele fraction of at least 2% and the absence of morphological evidence of malignancy or diagnostic criteria for paroxysmal nocturnal haemoglobinuria, monoclonal gammopathy of undetermined significance or monoclonal B-lymphocytosis.
- Hazard ratio
-
A statistical measure that corresponds to the probability of a particular outcome attributable to a given variable compared with normal controls.
- Annual risk
-
The probability of acquiring a condition over the course of 1 year.
- Idiopathic cytopenias of undetermined significance
-
(ICUS). Cytopenias that remain unexplained after thorough evaluation and do not meet World Health Organization criteria for a haematological neoplasm.
- de novo AML
-
Acute myeloid leukaemia (AML) that arises without a pre-existing myeloid neoplasm or a history of cytotoxic therapy. More common in younger patients and associated with an overall better prognosis.
- Induction therapy
-
High-dose intensive chemotherapy directed at inducing remission in acute leukaemias.
- Polycomb repressive complex
-
(PRC). Multiprotein complex involved in epigenetic repression of gene transcription.
- Cohesin complex
-
A multisubunit protein complex that forms a ring structure capable of encircling two chromosomal strands of DNA and is required for sister chromatid cohesion during mitosis.
- Core binding factor
-
A core haematopoietic transcription factor complex, mutations of which are associated with acute myeloid leukaemia in younger patients and a relatively good prognosis.
- Red cell distribution width
-
A measure of the distribution of red blood cell sizes; indicates the degree of variation within a sample.
- Polycythemia vera
-
(PV). Myeloproliferative neoplasm characterized by an elevated red blood cell count, and almost exclusively associated with activating mutations in Janus kinase 2 (JAK2).
- Essential thrombocythemia
-
(ET). Myeloproliferative neoplasm characterized by elevated platelet count, associated with mutations in Janus kinase 2 (JAK2), calreticulin (CALR) or MPL (gene that encodes the thrombopoietin receptor).
- Ring sideroblasts
-
Early red cell precursors containing aberrant mitochondrial iron staining; associated with mutations in splicing factors, most commonly splicing factor 3b subunit 1 (SF3B1).
- Conditioning regimens
-
High-dose preparative chemotherapy regimens given before stem cell transplantation. Can be either myeloablative (doses sufficient to completely ablate the bone marrow) or non-myeloablative.
Rights and permissions
About this article
Cite this article
Sperling, A., Gibson, C. & Ebert, B. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer 17, 5–19 (2017). https://doi.org/10.1038/nrc.2016.112
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc.2016.112
This article is cited by
-
The evolution of preclinical models for myelodysplastic neoplasms
Leukemia (2024)
-
Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia
Clinical Epigenetics (2023)
-
Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution—a proof of principle study
Virchows Archiv (2023)
-
Decoding the ‘Fifth’ Nucleotide: Impact of RNA Pseudouridylation on Gene Expression and Human Disease
Molecular Biotechnology (2023)
-
Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome
Nature Cell Biology (2022)